Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Overexpression”

36 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 36 results

Testing effectiveness (Phase 2)Study completedNCT00294762
What this trial is testing

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
OSI Pharmaceuticals 143
Large-scale testing (Phase 3)Looking for participantsNCT04928846
What this trial is testing

Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
AbbVie 768
Testing effectiveness (Phase 2)WithdrawnNCT05512182
What this trial is testing

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Who this might be right for
Recurrent/Advanced Gastric Cancer
Yonsei University
Early research (Phase 1)Study completedNCT00906698
What this trial is testing

Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2

Who this might be right for
Neoplasms
Boehringer Ingelheim 55
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT07712029
What this trial is testing

Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive

Who this might be right for
Advanced Refractory Solid TumorsEGFR Gene Overexpression
Tianjin Medical University Second Hospital 32
Testing effectiveness (Phase 2)Looking for participantsNCT07323641
What this trial is testing

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Who this might be right for
Lung Non-Small Cell Carcinoma
Jonsson Comprehensive Cancer Center 60
Large-scale testing (Phase 3)Looking for participantsNCT04415853
What this trial is testing

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Who this might be right for
Esophageal Cancer
Sunshine Lake Pharma Co., Ltd. 416
Testing effectiveness (Phase 2)Looking for participantsNCT06975410
What this trial is testing

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

Who this might be right for
EGFR OverexpressionLocally Advanced Solid TumorMetastatic Solid Tumor
Yuhan Corporation 80
Testing effectiveness (Phase 2)UnknownNCT04880811
What this trial is testing

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Who this might be right for
Esophageal Squamous Cell Carcinoma
Peking University 43
Testing effectiveness (Phase 2)Study completedNCT02748213
What this trial is testing

Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 225
Early research (Phase 1)Study completedNCT01255657
What this trial is testing

ABT-806 in Subjects With Advanced Solid Tumor Types

Who this might be right for
Advanced Solid Tumors
AbbVie (prior sponsor, Abbott) 49
Large-scale testing (Phase 3)Not Yet RecruitingNCT06908772
What this trial is testing

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Who this might be right for
Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Shanghai JMT-Bio Inc. 390
Early research (Phase 1)Study completedNCT01570296
What this trial is testing

A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR

Who this might be right for
Non-Small Cell Lung CancerSolid Tumors
National Cancer Centre, Singapore 38
Testing effectiveness (Phase 2)Looking for participantsNCT05315700
What this trial is testing

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Who this might be right for
Solid Tumors
ORIC Pharmaceuticals 350
Large-scale testing (Phase 3)Looking for participantsNCT06829459
What this trial is testing

Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

Who this might be right for
Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc. 350
Large-scale testing (Phase 3)Looking for participantsNCT07109531
What this trial is testing

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 286
Testing effectiveness (Phase 2)Looking for participantsNCT06343064
What this trial is testing

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 156
Testing effectiveness (Phase 2)UnknownNCT03940976
What this trial is testing

Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)

Who this might be right for
Esophageal Squamous Cell Carcinoma
Peking University 40
Testing effectiveness (Phase 2)Study completedNCT03329690
What this trial is testing

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Who this might be right for
Neoplasm, Gastrointestinal
Daiichi Sankyo Co., Ltd. 233
Next Page